Parathyroid Hormone-Related Protein 1-36

Parathyroid Hormone Related Protein (PTHrP) FragmentRx: ResearchCompound: Investigational

Also known as: hPTHrP(1-36), Parathyroid hormone-related peptide (1-36), PTHrP 1-36, PTHrP(1-36)

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

PTHrP(1-36) is an N-terminal fragment of parathyroid hormone-related protein that acts as a full agonist at the PTH1 receptor. It has been investigated as an anabolic agent for osteoporosis and has shown bone-forming activity in clinical studies. Unlike teriparatide (PTH 1-34), PTHrP(1-36) may have a more favorable cardiovascular and hypercalcemic profile in some contexts.

Mechanism of Action

Binds and activates the PTH1 receptor (PTH/PTHrP receptor), stimulating adenylyl cyclase and PKA signaling, promoting osteoblast activity, increasing bone formation, and modulating renal calcium and phosphate handling similar to PTH(1-34)

Routes of Administration

Subcutaneous

Goals & Uses

  • Anabolic bone therapyMusculoskeletalModerate
  • Hypercalcemia of malignancy researchOncology / Calcium MetabolismLow
  • Reduction of fracture riskOsteoporosisLow
  • Increase bone mineral densityBone HealthModerate

Contraindications

  • HypercalcemiaMetabolic DisorderHigh
  • Severe renal impairmentOrganModerateKidney function concerns
  • Paget's disease of boneBone DisorderModerate
  • History of skeletal malignancy or bone metastasesOncologyHigh

Adverse Effects

  • Elevated bone turnover markersLaboratoryCommon
  • Hypercalcemia / hypercalciuriaMetabolicCommon
  • Injection site reactionsLocalCommon
  • NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
  • Dizziness / orthostatic hypotensionCardiovascularUncommon

Drug Interactions

  • BisphosphonatesLow
  • DigoxinHigh
  • Calcium and Vitamin D supplementsLow
  • Thiazide diureticsModerate

Population Constraints

  • Pediatric patientsAgeRelative
  • Elderly patients (>75 years)AgeRelative
  • Pregnant womenReproductiveRelative
  • Patients with nephrolithiasis historyRenalRelative

Regulatory Status

  • European UnionInvestigationalNo marketing authorization; research use only
  • United StatesInvestigationalStudied under IND in Phase I/II trials; no NDA filed or approved as of knowledge cutoff
  • United KingdomInvestigationalNo MHRA approval; research compound

Not approved by FDA, EMA, or other major regulatory agencies. Studied in Phase I/II clinical trials for osteoporosis. No approved indication as of current knowledge cutoff.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack